PTGX logo

Protagonist Therapeutics, Inc. Stock Price

NasdaqGM:PTGX Community·US$4.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

PTGX Share Price Performance

US$76.72
30.76 (66.93%)
US$76.72
30.76 (66.93%)
Price US$76.72

PTGX Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
2 Rewards

Protagonist Therapeutics, Inc. Key Details

US$209.2m

Revenue

US$0

Cost of Revenue

US$209.2m

Gross Profit

US$157.1m

Other Expenses

US$52.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
0.84
100.00%
24.88%
0%
View Full Analysis

About PTGX

Founded
2006
Employees
130
CEO
Dinesh Patel
WebsiteView website
www.protagonist-inc.com

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Recent PTGX News & Updates

Recent updates

No updates